Compare AYTU & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | CCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 27.8M |
| IPO Year | 2015 | 2022 |
| Metric | AYTU | CCEL |
|---|---|---|
| Price | $2.45 | $3.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | ★ 29.6K | 9.0K |
| Earning Date | 05-13-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $27,632,080.00 | $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | $345.32 |
| Revenue Growth | ★ 277.47 | 9.76 |
| 52 Week Low | $1.26 | $2.72 |
| 52 Week High | $3.07 | $5.52 |
| Indicator | AYTU | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 48.45 |
| Support Level | $2.15 | $3.18 |
| Resistance Level | $2.64 | $3.57 |
| Average True Range (ATR) | 0.09 | 0.29 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 1.96 | 11.59 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.